Functional and Pharmacological Differences Between the Contractility of axoCells™ iPSC-Derived Atrial and Ventricular Cardiomyocytes Assessed on the FLEXcyte 96

he poster Functional and Pharmacological Differences Between the Contractility of axoCells™ iPSC-Derived Atrial and Ventricular Cardiomyocytes Assessed on the FLEXcyte 96 presents Axol Bioscience’s chamber-specific cardiomyocytes as a platform for cardiac pharmacology and arrhythmia research.

Key highlights include:

• Platform: FLEXcyte 96 system used to measure contractile force, beat rate, and beat duration
• Cell Types: Atrial and ventricular cardiomyocytes seeded at 65k cells/well and cultured for 6 days before compound treatment
• Waveform Analysis:
  • Atrial cells: shorter, rounded waveform with higher beat rate
  • Ventricular cells: longer waveform with plateau phase
• Pharmacological Profiling:
  • Carbachol: Decreased beat rate and increased beat duration in atrial cells; increased beat rate in ventricular cells
  • 4-AP: Decreased beat rate and increased beat duration in atrial cells; minimal effect on ventricular cells
  • S-Bay K8644: Transient decrease in beat rate in atrial cells; sustained increase in ventricular cells
• Chamber-Specific Insights:
  • Atrial cells show greater sensitivity to atrial-specific ion channel modulators
  • Ventricular cells demonstrate stronger calcium-induced contractility

This model supports predictive cardiac safety screening and subtype-specific drug development.

Featured Axol Products:

• axoCells™ Atrial Cardiomyocytes – ax2518
• axoCells™ Ventricular Cardiomyocytes – ax2508
• axoCells™ Cardiomyocyte Maintenance Media – ax2530